Adaptimmune to Present at Upcoming CAR-TCR Summit; CEO James Noble to be a Keynote Speaker

PHILADELPHIA and OXFORD, U.K., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced its participation in the CAR-TCR Summit in Boston on Tuesday, September 5, and Wednesday, September 6 at the Seaport Hotel & World Trade Center; One Seaport Lane, Boston, MA 02210.

The CAR-TCR summit highlights leaders in the CAR-T and TCR space to create a platform for cell immunotherapy experts to learn, network, and find solutions to their shared challenges. Adaptimmune’s representatives will give the following presentations:

• James Noble, Adaptimmune’s Chief Executive Officer, will be a keynote speaker in the Industry Leaders’ Fireside Chat on Wednesday, September 6, 2017 from 8:45AM EDT-10:15AM EDT.
• Samik Basu, Adaptimmune’s Director of Translational Science Research, will present at the Pre-Summit Deep Dive Day on Tuesday, September 5, 2017 from 3:00PM EDT-5:00PM EDT (Session G). He will discuss Understanding and Overcoming the Tumor Microenvironment.
• Helen Tayton-Martin, Adaptimmune’s Chief Business Officer, will present on Wednesday, September 6, 2017 from 11:50AM EDT-12:20PM EDT (CAR-TCR Commercialization Stream). She will discuss Building a Commercial Engineered T-Cell Therapy Strategy.
• Michael Blackton, Adaptimmune’s Vice President of Quality Assurance and CMC, will present on Wednesday, September 6, 2017 from 2:25PM EDT-2:55PM EDT (CAR-TCR Manufacturing Stream). He will discuss Applying Lifecycle Concepts to Advanced Stage T-Cell Product Development.

About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune has a number of proprietary clinical programs, and is also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and license agreement with GlaxoSmithKline. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com

Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 3, 2017, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contacts

Investor Relations
Juli P. Miller, Ph.D.
T: (215) 825-9310
E: juli.miller@adaptimmune.com

Media Relations
Margaret Henry
T: +44 (0)1235 430036
Cell: +44 (0)7710 304249
E: margaret.henry@adaptimmune.com

Released August 30, 2017